GR2301 injection with light therapy for vitiligo
Treatments studied
Part of Skin clinical trials.
This trial tests a new injection called GR2301 combined with light therapy to treat vitiligo, a condition that causes loss of skin color. The study aims to see if this combination helps restore skin color and reduce white patches.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have non-segmental vitiligo (the most common type) diagnosed at least 3 months before enrollment
- Have white patches affecting at least 0.5% of your face and at least 3% of your total body
- Be willing to receive injections and attend light therapy sessions as scheduled
- Not have had tattoos or skin grafts placed over your vitiligo patches
- Be able to follow medication rules and stop certain treatments before the trial starts
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cream for vitiligo on the face or neck. It aims to see if the cream can help bring color back to white patches.
This study tests a new medicine called LY4005130 for non-segmental vitiligo, a skin condition where patches lose pigment (color). The trial aims to see if this drug can help restore skin color and stop the spread of white patches.
This Phase 2 trial tests whether a new drug called D-2570 can help restore skin color in people with non-segmental vitiligo (when white patches appear randomly across the body). The study will track how well the drug works and check if it's safe to use.
This study tests a new medicine called FB102 for people with non-segmental vitiligo. It aims to see if the drug is safe and helps restore skin color.
This trial tests a new gel made from stem-cell substances (secretome) given with narrow-band UVB light therapy for stable non-segmental vitiligo. It compares two ways of applying the gel to see which works better.
This trial tests an ointment called MH004 to see if it helps repigment white patches in people with non-segmental vitiligo (the most common type). It focuses on patches on the face and body.
Hear when a new Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.